Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | C7R-GD2.CAR-T cells + i15.NKG2D.zeta NK cells |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| C7R-GD2.CAR-T cells | IL-7 Receptor Co-expressing GD2-specific CAR T-cells | C7R-GD2.CAR-T cells are autologous T-cells engineered to express a constitutively active IL7R (C7R) and a chimeric antigen receptor (CAR) targeting GD2, which may have antitumor activity against GD2-expressing tumor cells (PMID: 28830878). | ||
| i15.NKG2D.zeta NK cells | i15.NKG2D.zeta-NK cells | i15.NKG2D.zeta NK cells are primary natural killer (NK) cells engineered to express a chimeric receptor consisting of NKG2D linked to the the T-cell receptor zeta chain, which may lead to killing of myeloid-derived suppressor cells in the tumor microenvironment and enhanced CAR-T cell activity (PMID: 30651290). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07211737 | Phase I | C7R-GD2.CAR-T cells + i15.NKG2D.zeta NK cells | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | Not yet recruiting | USA | 0 |